Effect of steroid pulse therapy on mixed connective tissue disease with pulmonary arterial hypertension

Annals of the Rheumatic Diseases

Volumn 64, Issue 8, 2005, Pages 1236-1237

  Kamata, Y ^a   Nara, H ^a   Sato, H ^a   Masuyama, J I ^a   Minota, S ^a   Yoshio, T ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MEPREDNISONE; PREDNISONE; SILDENAFIL; STEROID;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; DOSE RESPONSE; DRUG PULSE THERAPY; ECHOCARDIOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; HEART CATHETERIZATION; HUMAN; LUNG FUNCTION TEST; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; MIXED CONNECTIVE TISSUE DISEASE; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SKIN TEMPERATURE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERTENSION, PULMONARY; METHYLPREDNISOLONE; MIXED CONNECTIVE TISSUE DISEASE; PIPERAZINES; VASODILATOR AGENTS;

EID: 23444446551     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.029074     Document Type: Article

References (9)

1. Tojo T. The 1996 revised criteria for MCTD. Annual report of the research committee for mixed connective tissue disease of the Ministry of Health and Welfare of Japan 1996:3.
2. Rosenkranz S, Diet F, Karasch T, Weihranch J, Wassermann K, Erdmann E. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 2003;139:871-3.
3. Morina J, Lucero E, Luluaga S, Bellomio V, Spindler A, Berman A. Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy. Lupus 2003;12:321-3.
4. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum 2003;48:282-3.
5. Yoshio T, Masuyama J-I, Sumiya M, Minota S, Kano K. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1994;21:2058-63.
6. Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, Sumiya M, et al. Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 1999;26:2357-62.
7. Mariette X, Brenot F, Brouet JC. Recovery from pulmonary hypertension with steroid therapy in a patient with Sjögren's syndrome and polymyositis. J Rheumatol 1994;21:772-3.
8. Sanchez O, Sitbon O, Garcia G, Jais X, Simonneau G, Humbert M. Pulmonary artery hypertension associated with connective tissue diseases. Presse Med 2003;32:789-99.
9. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(suppl S):68-72S.